Abstract

BackgroundCissampelos pareira L. (Menispermaceae) has been used in Indian traditional medicine for a variety of human ailments including diabetes mellitus. Although its anti-hyperglycemic activity has been validated by previous studies, a detailed mechanism of action and the responsible components are still unknown. PurposeThe present study aimed to evaluate the antidiabetic effect of aqueous-ethanolic extract of C. pareira roots in streptozotocin-nicotinamide (STZ-NAM)-induced diabetic rats via targeting SGLT2 inhibition. MethodsIn vitro α-amylase and α-glucosidase inhibitory assays were conducted using Epoch Microplate Spectrophotometer. A-498 cells viability assay and SGLT2 protein expression study were conducted using MTT assay and western blot respectively. STZ-NAM-induced diabetic rats were used as a model to evaluate the antidiabetic effect of the extract. Selected bioactive compounds reported earlier from the plant were studied for their in silico SGLT2 inhibitory activity. ResultsThe extract showed α-amylase and α-glucosidase inhibitory effects with IC50 values of 18.0 ± 1.01 and 4.87±0.54 mg/mL, respectively. A-498 cells viability assay showed its CC50 value of 0.8 mg/mL. The extract showed a notable effect on SGLT2 protein expression. The in vivo study revealed that the extract significantly (p<0.05) reduced the glucose levels in rats at the dose of 500 mg/kg, b.w. in a 28-days study. The molecular docking studies revealed insulanoline and warifteine as the most active compounds with docking scores of -10 and -9.9 kcal mol−1, respectively. ConclusionThe study showed that the extract has the potential to reduce STZ-induced elevated blood glucose without affecting liver and kidney functions.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call